People with TB Archives – Page 4 of 7

TB Research Investments Provide Returns in Combating Both TB and COVID-19

September 4, 2020
Dorrit Walsh

As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…

Demanding a Higher Standard of TB Care

September 2, 2020
Dorrit Walsh

In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

Cover image of publication, An Activist's Guide to Treatment for Drug Resistant TB

An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis

July 28, 2020
Dorrit Walsh

The 2020 updates to the World Health Organization (WHO) guidelines shifted the global standard of care for drug-resistant TB in a number of important ways. Our publication, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis, details these shifts and other…

Cover image of publication, An Activist's Guide to TB Diagnostic Tools

An Activist’s Guide to Tuberculosis Diagnostic Tools

July 28, 2020
Dorrit Walsh

Our publication, An Activist’s Guide to Tuberculosis Diagnostic Tools, details the latest WHO recommendations, the array of available TB diagnostic tools, and how these tools should be optimally used in country programs, including to support TB screening and diagnosis among special populations such as children, people with extrapulmonary TB, and people living with HIV/AIDS (PLWHA).

Treatment Action Group Statement on Bedaquiline Unaffordability

July 6, 2020
Dorrit Walsh

Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.

An Activist’s Guide to Rifapentine for the Treatment of TB Infection

April 30, 2020
Chad Cipiti

English version updated April 2020. The updated guide reflects new information from recently completed clinical trials, new WHO guidance on TB preventive therapy, and changes in rifapentine pricing and supply. Our publication, An Activist’s Guide to Rifapentine, details important efficacy,…

Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)

April 3, 2020
Dorrit Walsh

On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.

TAG Statement on WHO Updated TB Preventive Therapy Guidance

March 31, 2020
Dorrit Walsh

Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).

CROI 2020 TB Round Up

March 16, 2020
Dorrit Walsh

Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

March 3, 2020
Dorrit Walsh

Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.